Completed PHASE1 INTERVENTIONAL 4-arm NCT00449280

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies

Sponsor: Bayer

Updated 6 times since 2017 Last updated: Jun 11, 2013 Started: Nov 30, 2006 Primary completion: Jun 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumor and is currently completed. Bayer leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States